CD19 and neoplasm: observed the loss of CD19 on the tumor cells surface through flow cytometry analysis of B-ALL cells from patients with relapsed B-ALL after CD19-targeted CAR T cell therapy, and identified the genetic mutations of the CD19 gene by sequencing of the genomes of these B-ALL cells (94).